Skip to main content
. 2018 Oct 12;5(4):230–234. doi: 10.5152/eurjrheum.2018.18036

Figure 2. a, b.

Figure 2. a, b

Maximum CRP at baseline and after IL-1-blocking therapy (a); maximum SAA at baseline and after IL-1-blocking therapy (b)